Arcellx, Inc. is a clinical-stage biotechnology company. Co. is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. Co.'s lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). Co. is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). We show 9 historical shares outstanding datapoints in our ACLX shares outstanding history coverage, used to compute ACLX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ACLX market cap history over the course of time is important for investors
interested in comparing ACLX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ACLX versus a peer is one thing; comparing
ACLX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ACLX can fluctuate over the course of history.
With this page we aim to empower investors researching ACLX by allowing them to research the ACLX market cap history. |
Free ACLX Email Alerts:
Video: The Importance of Market Cap
